Plain-English translation of NCT07201558 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called , given by injection under the skin, for people with rheumatoid arthritis or systemic lupus erythematosus who haven't responded well to other treatments. The researchers want to understand how safe the medication is, how your body processes it, and how it affects your disease. You'll receive the medication once, twice, or three times depending on which part of the study you join.
Current treatments don't work well enough for everyone with these autoimmune diseases, and some people can't tolerate the medications that are available. This study aims to find out whether this new treatment could offer another option for people whose disease isn't controlled.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic to receive injections of the medication under your skin. Depending on which part of the study you're in, you'll receive one, two, or three doses over the course of several weeks. Throughout the study, you'll have blood tests, physical exams, and assessments of your joint symptoms to help researchers monitor how the medication is working and whether you experience any side effects. The entire study typically lasts several months.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States